Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Bronchiectasis and chronic obstructive pulmonary disease (COPD) are two chronic conditions that involve damage to the lungs. The causes and treatments for each differ. In some instances, COPD may ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...

The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

Please provide your email address to receive an email when new articles are posted on . Adults with a long-term smoking history suspected to have bronchiectasis faced an elevated mortality risk ...